📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The EU Risk Management Plan — a structured description of a medicine's safety profile and how its risks will be characterized and minimized.
Why it exists. European law requires an RMP with every marketing application. It lists the important identified and potential risks, missing information, the pharmacovigilance activities to study them, and the risk-minimization measures (e.g., label warnings, educational materials).
How it is produced here. It is a pharmacovigilance ('drug safety watch') document: it gathers and interprets the simulated safety data on the fixed schedule regulators expect once a drug enters development or the market.
Format & governing standard. GVP Module V (Rev 2) · EU-RMP template · ICH E2E
| Field | Value |
|---|---|
| Document ID | RMP-EU |
| Version | 2.0 (full GVP Module V) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Region | EMA (EU) |
| Standard | GVP Module V (Rev 2) · EU-RMP template · ICH E2E |
| Confidentiality | Confidential |
Safety concerns derive from the clinical AESIs (PROT-301 §10) and observed pivotal safety (CSR-301 §12). This EU-RMP is the ; the FDA risk-management assessment (RMP-US) and the MFDS RMP (RMP-KR) reference the same safety concerns with region-specific risk minimization.
No comments yet. Be the first to say something!
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Pharmacovigilance | Initial EU-RMP |
| 2.0 | 2026-06-29 | Pharmacovigilance | Full GVP Module V — elaborated safety concerns (SVII), PV plan, risk-minimization effectiveness |
GLPI-103 is a first-in-class GLP-1 / apelin (APJ) receptor dual agonist, supplied as an intravenous solution (once weekly) and an oral tablet (once daily), indicated for adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin, as add-on therapy. Pharmacotherapeutic group: drugs used in diabetes / GLP-1 analogues (with apelinergic activity). Background metformin is continued; dosing is titrated.
This is a structured inventory of what is known and not known about the drug's safety: the important identified risks, the potential ones, and the gaps (for example, groups not yet studied). Everything else in the plan flows from this list.
T2DM is a highly prevalent chronic disease; in the target Korean and broader populations, a large proportion of patients on metformin remain inadequately controlled. Important comorbidities (cardiovascular disease, chronic kidney disease, obesity) are common and inform the populations of interest and background event rates.
Nonclinical findings of relevance: reversible exaggerated-pharmacology gastrointestinal effects; injection-site reactions; class-appropriate thyroid C-cell monitoring; negative genotoxicity; maternal effects in reproductive studies. No adverse target-organ toxicity at therapeutic exposures; adequate margins (M2.4; M4-2.3).
Across the program, exposure includes Phase 1 (N=80), Phase 2 (N=240), and the pivotal Phase 3 study (N=900; up to 52 weeks). Exposure is summarized by dose, duration, age, sex, and region (REF-002; CSR-301).
Not adequately studied: pregnant/lactating women; children/adolescents; severe renal impairment (eGFR <45 excluded); severe hepatic impairment (ALT/AST >3×ULN excluded); very elderly (>75 excluded). These inform the missing information below.
None at initial authorization (new active substance).
Each safety concern is characterized below (evidence, mechanism, frequency, risk factors, preventability, pharmacovigilance, and risk minimization).
Important identified risk — Gastrointestinal adverse events (nausea, vomiting, diarrhoea)
Important identified risk — Hypoglycaemia (in combination with insulin secretagogues)
Important potential risk — Acute pancreatitis
Important potential risk — Thyroid C-cell tumours (MTC/MEN2)
Important potential risk — Cardiovascular / heart-rate effects (APJ-mediated)
Important potential risk — Immunogenicity
| Category | Safety concerns |
|---|---|
| Important identified risks | Gastrointestinal AEs; hypoglycaemia (with secretagogues) |
| Important potential risks | Acute pancreatitis; thyroid C-cell tumours (MTC/MEN2); cardiovascular/heart-rate effects; immunogenicity |
| Missing information | Pregnancy/lactation; paediatric use; severe renal/hepatic impairment; long-term & cardiovascular-outcomes safety |
A cardiovascular/heart-failure outcomes study is proposed to substantiate the APJ-mediated cardiometabolic positioning (lifecycle; CDP).
Most risks are managed simply by the label ('routine'). A few may need 'additional' measures — educational materials, controlled access, pregnancy-prevention programs. This part states which risks need more than the label, and why.
| Safety concern | Routine (SmPC/PL) | Additional | Effectiveness indicator |
|---|---|---|---|
| Gastrointestinal AEs | Posology/titration; §4.2/4.8 | HCP education (if warranted) | Discontinuation/AE rates in PASS |
| Hypoglycaemia | §4.4 warning; secretagogue advice | Patient materials (if warranted) | Hypoglycaemia rates |
| Pancreatitis | §4.4 warning; discontinue if suspected | Follow-up questionnaire | Confirmed-case rate |
| Thyroid C-cell/MTC | §4.3 contraindication; §4.4 warning | — | Signal review |
| Cardiovascular/HR | §4.4 monitoring | CV outcomes study | CV event rates |
| Immunogenicity | — | ADA monitoring in studies | ADA incidence/impact |
Routine risk minimization (SmPC/Package Leaflet), supported by the pharmacovigilance plan and post-authorization studies, adequately characterizes and manages the identified and potential risks; missing information is addressed by the PASS and pregnancy registry. The benefit–risk remains favourable (M2.5.6).
AESI definitions (PROT-301 §10, Appendix B), targeted follow-up questionnaires, PASS/registry protocol synopses, and the benefit–risk conclusion (M2.5.6).